.png)
Low-dose Psilocybin: Metabolic Benefits Without Psychedelic Effects
- Jan 29
- 1 min read
Microdosing Psilocybin Shows Promise for Obesity-Related Diseases
A new preclinical study from Italian researchers suggests psilocybin could improve metabolic health—even at doses too low to be psychedelic.
In the study, mice on a high-fat, high-sugar diet received tiny doses of psilocybin for 12 weeks. The results were striking:
Reduced weight gain
Improved insulin sensitivity
Normalized blood glucose
Regression of fatty liver disease
What’s particularly interesting is that these benefits happened without affecting appetite or the central nervous system. The effects appear to come from psilocybin interacting with serotonin receptors in the liver, not the ones that cause hallucinations.
Additional findings included better muscle function and recovery of insulin-producing pancreatic cells—pointing to a broader impact on metabolic health.
While this research is still in animal models, it highlights potential applications for psilocybin beyond mental health, opening doors to future therapies for obesity, type 2 diabetes, and fatty liver disease.